A Jehovah’s Witness with Acute Myeloid Leukemia Successfully Treated with an Epigenetic Drug, Azacitidine: A Clue for Development of Anti-AML Therapy Requiring Minimum Blood Transfusions
Joint Authors
Yamamoto, Yumi
Kawashima, Akihito
Kashiwagi, Eri
Ogata, Kiyoyuki
Source
Issue
Vol. 2014, Issue 2014 (31 Dec. 2014), pp.1-4, 4 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2014-10-02
Country of Publication
Egypt
No. of Pages
4
Main Subjects
Abstract EN
Therapy for acute leukemia in Jehovah’s Witnesses patients is very challenging because of their refusal to accept blood transfusions, a fundamental supportive therapy for this disease.
These patients are often denied treatment for fear of treatment-related death.
We present the first Jehovah’s Witness patient with acute myeloid leukemia (AML) treated successfully with azacitidine.
After achieving complete remission (CR) with one course of azacitidine therapy, the patient received conventional postremission chemotherapy and remained in CR.
In the case of patients who accept blood transfusions, there are reports indicating the treatment of AML patients with azacitidine.
In these reports, azacitidine therapy was less toxic, including hematoxicity, compared with conventional chemotherapy.
The CR rate in azacitidine-treated patients was inadequate; however, some characteristics could be useful in predicting azacitidine responders.
The present case is useful for treating Jehovah’s Witnesses patients with AML and provides a clue for anti-AML therapy requiring minimum blood transfusions.
American Psychological Association (APA)
Yamamoto, Yumi& Kawashima, Akihito& Kashiwagi, Eri& Ogata, Kiyoyuki. 2014. A Jehovah’s Witness with Acute Myeloid Leukemia Successfully Treated with an Epigenetic Drug, Azacitidine: A Clue for Development of Anti-AML Therapy Requiring Minimum Blood Transfusions. Case Reports in Hematology،Vol. 2014, no. 2014, pp.1-4.
https://search.emarefa.net/detail/BIM-1017085
Modern Language Association (MLA)
Yamamoto, Yumi…[et al.]. A Jehovah’s Witness with Acute Myeloid Leukemia Successfully Treated with an Epigenetic Drug, Azacitidine: A Clue for Development of Anti-AML Therapy Requiring Minimum Blood Transfusions. Case Reports in Hematology No. 2014 (2014), pp.1-4.
https://search.emarefa.net/detail/BIM-1017085
American Medical Association (AMA)
Yamamoto, Yumi& Kawashima, Akihito& Kashiwagi, Eri& Ogata, Kiyoyuki. A Jehovah’s Witness with Acute Myeloid Leukemia Successfully Treated with an Epigenetic Drug, Azacitidine: A Clue for Development of Anti-AML Therapy Requiring Minimum Blood Transfusions. Case Reports in Hematology. 2014. Vol. 2014, no. 2014, pp.1-4.
https://search.emarefa.net/detail/BIM-1017085
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1017085